Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation and Depletion: 2012-2020

Historic Depreciation and Depletion for Agios Pharmaceuticals (AGIO) over the last 7 years, with Jun 2020 value amounting to $2.4 million.

  • Agios Pharmaceuticals' Depreciation and Depletion rose 19.39% to $2.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $8.9 million, marking a year-over-year increase of 13.96%. This contributed to the annual value of $5.7 million for FY2024, which is 13.64% down from last year.
  • As of Q2 2020, Agios Pharmaceuticals' Depreciation and Depletion stood at $2.4 million, which was down 1.70% from $2.5 million recorded in Q1 2020.
  • In the past 5 years, Agios Pharmaceuticals' Depreciation and Depletion registered a high of $2.5 million during Q1 2020, and its lowest value of $1.2 million during Q1 2016.
  • For the 3-year period, Agios Pharmaceuticals' Depreciation and Depletion averaged around $2.0 million, with its median value being $2.0 million (2018).
  • Per our database at Business Quant, Agios Pharmaceuticals' Depreciation and Depletion skyrocketed by 236.76% in 2016 and then decreased by 5.81% in 2017.
  • Over the past 5 years, Agios Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $1.7 million in 2016, then fell by 5.81% to $1.6 million in 2017, then grew by 19.54% to $1.9 million in 2018, then fell by 3.25% to $1.9 million in 2019, then rose by 19.39% to $2.4 million in 2020.
  • Its Depreciation and Depletion was $2.4 million in Q2 2020, compared to $2.5 million in Q1 2020 and $1.9 million in Q4 2019.